Literature DB >> 1851790

Characterization of angiotensin peptides in plasma of anephric man.

D J Campbell1, A Kladis, S L Skinner, J A Whitworth.   

Abstract

Recent evidence suggests that a considerable proportion of plasma angiotensin is generated not in blood but in peripheral tissues. Through the measurement of angiotensin peptides and renin in the plasma of 11 anephric subjects, we have investigated whether kidney-derived renin, or some other tissue mechanism for angiotensin generation, is the major determinant of plasma angiotensin. Particular care was taken to prevent inadvertent activation of inactive renin and possible generation, conversion and metabolism of angiotensin peptides during processing of blood samples. Initial experiments revealed that plasma from anephric subjects contains high amounts of material which interferes in radioimmunoassays for angiotensin, even after high-performance liquid chromatography (HPLC). Therefore, in order to obtain an unambiguous identification of angiotensin peptides, a dual HPLC method was developed in which angiotensin peptides were first separated by HPLC, then acetylated and run again on HPLC before radioimmunoassay for angiotensin I and II (detection limits, 0.25 and 0.2 fmol/ml, respectively). The levels of angiotensin I and II were 1.2 +/- 1.6 and 0.7 +/- 0.5 fmol/ml (mean +/- s.d., n = 9-10), respectively, being 6% of levels in normal subjects, and were consistent with the active renin levels (1.8 +/- 1.7 muIU/ml, n = 11) which were 7% of levels in normal subjects. Artefactual activation of prorenin and angiotensin generation during sample processing were excluded as significant causes of the low levels of active renin and angiotensin I and II in anephric plasma. These data indicate that kidney-derived renin is the major determinant of angiotensin levels in normal human plasma. However, the present demonstration of low levels of active renin and angiotensin I and II in plasma of anephric subjects provides unequivocal evidence for a functional extrarenal renin-angiotensin system in man.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851790     DOI: 10.1097/00004872-199103000-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  12 in total

1.  Increased dietary NaCl potentiates the effects of elevated prorenin levels on blood pressure and organ disease.

Authors:  Duncan J Campbell; Habib Karam; Patrick Bruneval; John J Mullins; Joël Ménard
Journal:  J Hypertens       Date:  2010-07       Impact factor: 4.844

2.  Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy.

Authors:  Carlos M Ferrario; Jasmina Varagic; Javad Habibi; Sayaka Nagata; Johji Kato; Mark C Chappell; Aaron J Trask; Kazuo Kitamura; Adam Whaley-Connell; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-13       Impact factor: 4.733

3.  Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system.

Authors:  Hua Peng; Dane D Jensen; Wencheng Li; Michelle N Sullivan; Sophie A Buller; Caleb J Worker; Silvana G Cooper; Shiqi Zheng; Scott Earley; Curt D Sigmund; Yumei Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-15       Impact factor: 4.733

4.  Increased (pro)renin receptor expression in the subfornical organ of hypertensive humans.

Authors:  Silvana G Cooper; Darshan P Trivedi; Rieko Yamamoto; Caleb J Worker; Cheng-Yuan Feng; Jacob T Sorensen; Wei Yang; Zhenggang Xiong; Yumei Feng
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-12-22       Impact factor: 4.733

Review 5.  New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Peptides       Date:  2011-06-14       Impact factor: 3.750

6.  Plasma and serum prorenin concentrations in diabetes, hypertension, and renal disease.

Authors:  Sayuki Kawamura; Kazumi Fujimoto; Akinori Hayashi; Yuji Kamata; Ibuki Moriguchi; Naoyuki Kobayashi; Masayoshi Shichiri
Journal:  Hypertens Res       Date:  2022-06-10       Impact factor: 5.528

Review 7.  Clinical pharmacokinetics and efficacy of renin inhibitors.

Authors:  G A Rongen; J W Lenders; P Smits; T Thien
Journal:  Clin Pharmacokinet       Date:  1995-07       Impact factor: 6.447

8.  Lack of correlation between the acute haemodynamic response to intravenous captopril and plasma concentrations of angiotensin II in patients with chronic cardiac failure.

Authors:  A D Flapan; T R Shaw; C R Edwards; M Rademaker; E Davies; B C Williams
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

9.  Longitudinal Changes in Prorenin and Renin in the Chronic Renal Insufficiency Cohort.

Authors:  Monique E Cho; Carol Sweeney; Nora Fino; Tom Greene; Nirupama Ramkumar; Yufeng Huang; Ana C Ricardo; Tariq Shafi; Rajat Deo; Amanda Anderson; Katherine T Mills; Alfred K Cheung
Journal:  Am J Nephrol       Date:  2021-03-18       Impact factor: 3.754

10.  Circulating prorenin: its molecular forms and plasma concentrations.

Authors:  Kazumi Fujimoto; Sayuki Kawamura; Satoru Bando; Yuji Kamata; Yoshio Kodera; Masayoshi Shichiri
Journal:  Hypertens Res       Date:  2021-02-10       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.